OMER
Closed
Omeros Corporation
2.97
-0.03 (-1.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 3.
Day's Range: 2.95 - 3.2
Send
sign up or login to leave a comment!
When Written:
4.79
Omeros Corporation is a biopharmaceutical company that develops and commercializes drugs for various diseases. The company was founded in 1994 and is headquartered in Seattle, Washington. Omeros' primary focus is on developing treatments for diseases related to the central nervous system, inflammation, and ophthalmology.
The company's flagship product is Omidria, a drug used during cataract surgery and intraocular lens replacement to prevent intraoperative miosis (pupil constriction) and reduce postoperative pain and inflammation. Omeros is also developing drugs for Huntington's disease, addiction, and acute respiratory distress syndrome (ARDS).
Omeros has partnerships with various pharmaceutical companies, including Lonza, Pfizer, and GPCR Therapeutics, to develop and commercialize its products. The company has received funding from various sources, including the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation.
As of 2021, Omeros has a market capitalization of approximately $1.1 billion and employs over 300 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company's flagship product is Omidria, a drug used during cataract surgery and intraocular lens replacement to prevent intraoperative miosis (pupil constriction) and reduce postoperative pain and inflammation. Omeros is also developing drugs for Huntington's disease, addiction, and acute respiratory distress syndrome (ARDS).
Omeros has partnerships with various pharmaceutical companies, including Lonza, Pfizer, and GPCR Therapeutics, to develop and commercialize its products. The company has received funding from various sources, including the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation.
As of 2021, Omeros has a market capitalization of approximately $1.1 billion and employs over 300 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!
When Written:
4.79
Omeros Corporation is a biopharmaceutical company based in Seattle, Washington. The company focuses on developing and commercializing small-molecule and protein therapeutics for the treatment of inflammation, coagulopathies, and disorders of the central nervous system.
Omeros' lead product, Omidria, is an FDA-approved drug used during cataract surgery and intraocular lens replacement to prevent intraoperative miosis (pupil constriction) and reduce postoperative pain. The company is also developing a pipeline of products targeting complement-mediated diseases, including rare disorders such as atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
In addition to its clinical programs, Omeros has a proprietary platform technology called PharmacoSurgery, which is designed to improve surgical outcomes by reducing inflammation and pain.
Founded in 1994, Omeros went public in 2009 and is traded on the NASDAQ stock exchange under the ticker symbol OMER.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Omeros' lead product, Omidria, is an FDA-approved drug used during cataract surgery and intraocular lens replacement to prevent intraoperative miosis (pupil constriction) and reduce postoperative pain. The company is also developing a pipeline of products targeting complement-mediated diseases, including rare disorders such as atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria.
In addition to its clinical programs, Omeros has a proprietary platform technology called PharmacoSurgery, which is designed to improve surgical outcomes by reducing inflammation and pain.
Founded in 1994, Omeros went public in 2009 and is traded on the NASDAQ stock exchange under the ticker symbol OMER.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!